Latest news with #EXPAREL
Business Journals
12-05-2025
- Health
- Business Journals
Prioritizing pain relief after plastic surgery with non-opioid pain therapies
Plastic surgery has become increasingly popular, with millions of Americans undergoing procedures such as tummy tucks, breast augmentations, rhinoplasties and more each year. Here in Miami, my patients not only come to me with clear aesthetic goals but, just as often, they voice concerns about the recovery and how painful it may be. As a plastic surgeon, I recognize that my patients have busy lives and that they can't wait for a long recovery period. And while recovery can be one of the most stressful parts of the surgical journey, I've found that effective pain management isn't just about comfort. It's essential for patient safety, a smoother recovery and long-term satisfaction as well. For years, opioids have been the go-to solution for managing postsurgical pain. However, they are often associated with several unwanted side effects that can complicate and delay recovery such as nausea, constipation, drowsiness and the risk of dependence. Considering that overdose remains the leading cause of death for Americans aged 18-44, I believe it's our responsibility as health care providers to do better. That's why I've made it a priority in my practice to reduce the use of opioids and turn to safer, non-opioid therapies that still give my patients the relief they need. A 'pain package' that puts patients first In nearly every procedure I perform, I use EXPAREL® (bupivacaine liposome injectable suspension) to help manage my patients' pain during recovery. EXPAREL is a long-acting local anesthetic that is injected directly into the surgical site and provides targeted pain relief for the first 48 to 72 hours after surgery. This window is crucial because it is when pain is usually the most intense, and often when patients typically turn to opioids to manage the pain. I combine EXPAREL with intravenous (IV) Tylenol and gabapentin as part of an extended, multimodal 'pain package.' This approach allows me to stay ahead of pain from the beginning, so patients wake up from surgery feeling more at ease and less anxious about what's ahead. With this strategy, many of my patients can significantly reduce and, in some cases, completely avoid opioids altogether. Reducing risks and enhancing recovery Since incorporating EXPAREL into my pain management protocol, I've seen a remarkable shift in the overall recovery experience for my patients. Most notably, patients can get out of bed and start moving sooner. This is an important recovery milestone because it helps reduce swelling and lowers the risk of blood clots, a serious concern following many plastic surgery procedures. Another major advantage of minimizing the use of opioids is avoiding often-overlooked side effects like constipation. This is especially important for abdominoplasty patients, many of whom used to tell me that the pain from constipation was worse than the surgery itself. It's not always a comfortable topic, but it's a real issue. And, since using EXPAREL, I've seen a noticeable reduction in these complaints, along with fewer calls from patients struggling with pain or discomfort in the early days of healing. Encouraging patient empowerment Whether you're considering cosmetic surgery for yourself or supporting a loved one through the process, pain management is a critical part of the surgical journey. It's not just about getting through the first few days; it can completely shape your recovery experience and have a lasting impact on how you feel about your results. In every consultation, I take time to walk patients through how EXPAREL works and how it fits into their personalized care plan. I encourage anyone preparing for surgery to ask their health care provider about non-opioid options like EXPAREL. Having these conversations is the first step toward a smoother, simpler recovery that lets you focus on feeling like yourself again. expand *Dr. Zuriarrain is a consultant of Pacira BioSciences, Inc. This is based on Dr. Zuriarrain's experiences. Individual patient experiences may vary. Indication: EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks. Important safety information: EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, headache, and constipation. In the study where EXPAREL was given to children, the most common side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to five days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound, for patients younger than 18 years old for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into the joints; and can cause a rare blood disorder. Full Prescribing Information is available at .
Yahoo
14-03-2025
- Business
- Yahoo
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC ('DOMA') has nominated three candidates to stand for election to the Pacira Board of Directors (the 'Board') at the Company's 2025 Annual Meeting of Stockholders. Pacira issued the following statement in response to DOMA's director nominations: 'Pacira's Board and management team are taking decisive action to enhance shareholder value. We recently completed a comprehensive portfolio review and defined our 5x30 plan as the best plan to deliver shareholder value. The Nominating, Governance and Sustainability Committee of the Pacira Board will evaluate and consider DOMA's proposed candidates, as it does with all director candidates.' The Board will present its formal recommendation regarding director nominees in the Company's definitive proxy statement and other materials, to be filed with the Securities and Exchange Commission and mailed to all shareholders eligible to vote at the 2025 Annual Meeting of Stockholders. The date of the Annual Meeting has not yet been announced and shareholders are not required to take any action at this time. Evercore is serving as financial advisor and Wachtell, Lipton, Rosen & Katz is serving as legal advisor to the Company. About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®°, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit Forward-Looking Statements Any statements in this document about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words 'believes,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'intends,' 'may,' 'will,' 'would,' 'could,' 'can' and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2025 Annual Meeting, '5x30', Pacira's growth and business strategy; Pacira's future outlook, Pacira's intellectual property and patent terms, Pacira's growth and future operating results and trends, Pacira's strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including Pacira's plans with respect to the repayment of Pacira's indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. Pacira cannot assure you that its estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; Pacira's manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and Pacira's business, including Pacira's revenues, financial condition, cash flow and results of operations; the success of Pacira's sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and Pacira's ability to serve those markets; Pacira's plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; Pacira's plans to evaluate, develop and pursue additional product candidates utilizing Pacira's proprietary multivesicular liposome ('pMVL') drug delivery technology; the approval of the commercialization of Pacira's products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; Pacira's commercialization and marketing capabilities; Pacira's ability to successfully complete capital projects; the outcome of any litigation; the recoverability of Pacira's deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of Pacira's share repurchase program; and factors discussed in the 'Risk Factors' of Pacira's most recent Annual Report on Form 10-K and in other filings that it periodically makes with the SEC. In addition, the forward-looking statements included in this document represent Pacira's views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira's views as of any date subsequent to the date of this document. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira's actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the 'Risk Factors' of Pacira's most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC. Important Additional Information Regarding Proxy Solicitation Pacira intends to file a proxy statement and BLUE proxy card with the U.S. Securities and Exchange Commission (the 'SEC') in connection with its solicitation of proxies for Pacira's 2025 annual meeting of stockholders (the '2025 Proxy Statement,' and such meeting the '2025 Annual Meeting'). BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING PACIRA'S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC's website at and on Pacira's investor relations website at Participants in the Solicitation Pacira, its directors, director nominees, certain of its executive officers and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2025 Annual Meeting. Information regarding the names of Pacira's directors and executive officers and their respective interests in Pacira by security holdings or otherwise is set forth in Pacira's proxy statement for the 2024 Annual Meeting of stockholders, filed with the SEC on April 22, 2024 (the '2024 Proxy Statement'). Please refer to the sections captioned 'Director Compensation,' 'Executive Compensation,' and 'Stock Ownership Information' in the 2024 Proxy Statement. To the extent holdings of such participants in Pacira's securities have changed since the amounts described in the 2024 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Changes in Beneficial Ownership of Securities on Form 4 filed with the SEC: Form 4, filed by Jonathan Slonin on June 5, 2024; Form 4, filed by Daryl Gaugler on June 5, 2024; Form 4, filed by Kristen Williams on June 5, 2024; Form 4, filed by Lauren Riker on June 5, 2024; Form 4, filed by Mark A. Kronenfeld on June 13, 2024; Form 4, filed by Laura Brege on June 13, 2024; Form 4, filed by Kristen Williams on June 13, 2024; Form 4, filed by Alethia Young on June 13, 2024; Form 4, filed by Mark Froimson on June 13, 2024; Form 4, filed by Daryl Gaugler on June 13, 2024; Form 4, filed by Abraham Ceesay on June 13, 2024; Form 4, filed by Michael J. Yang on June 13, 2024; Form 4, filed by Marcelo Bigal on June 13, 2024; Form 4, filed by Christopher Christie on June 13, 2024; Form 4, filed by Jonathan Slonin on June 13, 2024; Form 4, filed by Lauren Riker on June 13, 2024; Form 4, filed by Jonathan Slonin on July 3, 2024; Form 4, filed by Daryl Gaugler on July 3, 2024; Form 4, filed by Jonathan Slonin on August 2, 2024; Form 4, filed by Marcelo Bigal on August 12, 2024; Form 4, filed by Mark Froimson on August 12, 2024; Form 4/A, filed by Marcelo Bigal on August 13, 2024; Form 4, filed by Frank D. Lee on August 13, 2024; Form 4, filed by Michael J. Yang on August 14, 2024; Form 4, filed by Laura Brege on August 19, 2024; Form 4, filed by Marcelo Bigal on August 19, 2024; Form 4, filed by Daryl Gaugler on September 13, 2024; Form 3, filed by Shawn Cross on October 23, 2024; Form 4, filed by Shawn Cross on November 5, 2024; Form 4, filed by Daryl Gaugler on December 16, 2024; Form 4, filed by Lauren Riker on January 6, 2025; Form 4, filed by Daryl Gaugler on January 6, 2025; Form 4, filed by Jonathan Slonin on January 6, 2025; Form 4, filed by Frank D. Lee on January 6, 2025; Form 3, filed by Brendan Teehan on January 28, 2025; Form 4, filed by Lauren Riker on February 4, 2025; Form 4, filed by Brendan Teehan on February 4, 2025; Form 4, filed by Frank D. Lee on February 4, 2025; Form 4, filed by Kristen Williams on February 4, 2025; and Form 4, filed by Jonathan Slonin on February 4, 2025. Additional information can also be found in Pacira's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on February 27, 2025. Details concerning potential participants in the solicitation, including Pacira's director nominees for election at the 2025 Annual Meeting, will also be included in the 2025 Proxy Statement. These documents, including the definitive 2025 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC's website at and on Pacira's investor relations website at CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 Media Contact: Sara Marino, (973) 370-5430
